Although EML4–ALK fusions are observed in only 4%–5% of yearly diagnosed non-small cell lung cancer cases, the remarkable response to ALK inhibitor drugs has led to universal testing for all patients with advanced non-small cell lung cancer (Kurnit et al., 2019). This evidence concerns the gene ALK and non-small cell lung carcinoma.